Item 1.01 Entry into a Material Definitive Agreement.
On
Under the Collaboration and License Agreement, the Company granted Moderna an exclusive, worldwide, royalty-bearing license under certain Company intellectual property to develop, manufacture, commercialize and otherwise exploit licensed products ("Licensed Products") for all human and non-human diagnostic, prophylactic and therapeutic uses, subject to certain exceptions with respect to Licensed Products within certain Collaboration Programs, and a non-exclusive, worldwide, royalty-free license under certain Company intellectual property to conduct pre-clinical research in accordance with work plans under the Collaboration and License Agreement. Moderna granted the Company a non-exclusive, worldwide, royalty-free license under certain intellectual property of Moderna to conduct preclinical research and discovery in accordance with work plans under the Collaboration and License Agreement. Each party has the right to sublicense its rights under the Collaboration and License Agreement subject to certain conditions.
Under the terms of the Collaboration and License Agreement, Moderna will make an
upfront cash payment to the Company of
The Collaboration and License Agreement also provides Moderna with a one-time option to participate in a future equity financing by the Company subject to certain terms, conditions and regulatory requirements.
The Collaboration and License Agreement will continue in effect on a Licensed Product-by-Licensed Product and country-by-country basis until the expiration of the obligation to make payments under the Collaboration and License Agreement with respect to such Licensed Product in each country, unless earlier terminated by either party pursuant to its terms. Either the Company or Moderna may terminate the Collaboration and License Agreement for the other party's insolvency or certain uncured breaches or if the other party or any of its sublicensees or affiliates challenge certain patents of such party and such challenge is not rescinded within sixty (60) days. In addition, Moderna may terminate the Collaboration and License Agreement on a Licensed Product-by-Licensed Product or Collaboration Program-by-Collaboration Program basis effective immediately upon written notice to the Company if Moderna believes in good faith that it is not advisable to continue to develop or commercialize any Licensed Product in such Collaboration Program as a result of a perceived serious safety issue. Moderna also may terminate the Collaboration and License Agreement in its entirety after the second anniversary of the effective date of the Collaboration and License Agreement subject to certain conditions within specified time periods in the Collaboration and License Agreement. Moderna also may terminate the Collaboration and License Agreement on a Licensed Product-by-Licensed Product basis at any time subject to certain conditions within specified time periods in the Collaboration and License Agreement.
The foregoing summary of the material terms and conditions of the Collaboration
and License Agreement is qualified in its entirety by the full agreement, a copy
of which will be filed as an exhibit to the Company's Annual Report on Form 10-K
for the year ended
--------------------------------------------------------------------------------
© Edgar Online, source